Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 24 May 2022 for PhaseBio Pharmaceuticals Inc, €3,881. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
John P. Sharp: trading record in brief
John P. Sharp (finance chief) discloses dealings in PhaseBio Pharmaceuticals Inc to SEC (Form 4). Over a trading history stretching from 20 May 2021 to 20 May 2022, the count stands at 6 filings.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Most recently, on 24 May 2022, the filings show a share grant worth €3,881 in PhaseBio Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to John P. Sharp
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
6,026 shares@ US$0.68134.7% of flowCommon StockSEC:0001169245-22-000074:0
2,017 shares@ US$2.0111.1% of flowCommon StockSEC:0001169245-21-000127:0
7,500 shares@ US$1.6833.8% of flowCommon StockSEC:0001169245-21-000103:0
7,500 shares@ US$1.6813.0% of flowCommon StockSEC:0001169245-21-000087:0
7,500 shares@ US$1.6833.0% of flowCommon StockSEC:0001169245-21-000071:0
1,419 shares@ US$2.807.6% of flowCommon StockSEC:0001169245-21-000047:0
6 of 6 declarations
